ccr5 antagonist dapta Search Results


ccr5 antagonist dapta  (Tocris)
92
Tocris ccr5 antagonist dapta
Ccr5 Antagonist Dapta, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccr5+antagonist+dapta/DAPTA/pmc04957133-36-34-41
Average 92 stars, based on 1 article reviews
ccr5 antagonist dapta - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
ccr5 antagonist d-ala 1 -peptide t-nh 2 ; dapta  (Bachem)
90
Bachem ccr5 antagonist d-ala 1 -peptide t-nh 2 ; dapta
Mean clinical scores of age- and sex-matched control mice after saline and <t>CCR5</t> +/+ and CCR5 −/− mice after induction of EAE with MOG 35-55 A. Control mice group had no symptoms B. Maximal mean score was 1.8±0.2 in MOG 35-55 -immunized CCR5 −/− mice and 3.1±1.2 in MOG 35-55 -immunized CCR5 +/+ mice. Mean day of onset was the same for CCR5 +/+ (11.8±1.8) and CCR5 −/− (11.2±1.8) mice. Mean body weight (g) was compared to day 0 in each group after injection of saline or MOG 35-55 for 28 days C. At day 28, control mouse body weight had increased 3.8±2.2 g, but had decreased 3.2±3.2 g and 2.6±3.0 g in MOG35-55-immunized CCR5 +/+ and CCR5 −/− mice, respectively. Weight loss (%) was not different between MOG 35-55 -induced CCR5 +/+ (14.6±13.8) and CCR5 −/− (11.4±13.4) mice D. Values are presented as mean ± SEM. # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.
Ccr5 Antagonist D Ala 1 Peptide T Nh 2 ; Dapta, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccr5+antagonist+dapta/ccr5+peptides/pmc04941248-116-25-34
Average 90 stars, based on 1 article reviews
ccr5 antagonist d-ala 1 -peptide t-nh 2 ; dapta - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
c57bl/6 mouse  (Inotiv)
99
Inotiv c57bl/6 mouse
Mean clinical scores of age- and sex-matched control mice after saline and <t>CCR5</t> +/+ and CCR5 −/− mice after induction of EAE with MOG 35-55 A. Control mice group had no symptoms B. Maximal mean score was 1.8±0.2 in MOG 35-55 -immunized CCR5 −/− mice and 3.1±1.2 in MOG 35-55 -immunized CCR5 +/+ mice. Mean day of onset was the same for CCR5 +/+ (11.8±1.8) and CCR5 −/− (11.2±1.8) mice. Mean body weight (g) was compared to day 0 in each group after injection of saline or MOG 35-55 for 28 days C. At day 28, control mouse body weight had increased 3.8±2.2 g, but had decreased 3.2±3.2 g and 2.6±3.0 g in MOG35-55-immunized CCR5 +/+ and CCR5 −/− mice, respectively. Weight loss (%) was not different between MOG 35-55 -induced CCR5 +/+ (14.6±13.8) and CCR5 −/− (11.4±13.4) mice D. Values are presented as mean ± SEM. # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.
C57bl/6 Mouse, supplied by Inotiv, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ccr5+antagonist+dapta/C57BL%2F6+Mouse/custom%40c57bl_6_mouse%4029417414
Average 99 stars, based on 1 article reviews
c57bl/6 mouse - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


Mean clinical scores of age- and sex-matched control mice after saline and CCR5 +/+ and CCR5 −/− mice after induction of EAE with MOG 35-55 A. Control mice group had no symptoms B. Maximal mean score was 1.8±0.2 in MOG 35-55 -immunized CCR5 −/− mice and 3.1±1.2 in MOG 35-55 -immunized CCR5 +/+ mice. Mean day of onset was the same for CCR5 +/+ (11.8±1.8) and CCR5 −/− (11.2±1.8) mice. Mean body weight (g) was compared to day 0 in each group after injection of saline or MOG 35-55 for 28 days C. At day 28, control mouse body weight had increased 3.8±2.2 g, but had decreased 3.2±3.2 g and 2.6±3.0 g in MOG35-55-immunized CCR5 +/+ and CCR5 −/− mice, respectively. Weight loss (%) was not different between MOG 35-55 -induced CCR5 +/+ (14.6±13.8) and CCR5 −/− (11.4±13.4) mice D. Values are presented as mean ± SEM. # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.

Journal: Oncotarget

Article Title: CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice

doi: 10.18632/oncotarget.8097

Figure Lengend Snippet: Mean clinical scores of age- and sex-matched control mice after saline and CCR5 +/+ and CCR5 −/− mice after induction of EAE with MOG 35-55 A. Control mice group had no symptoms B. Maximal mean score was 1.8±0.2 in MOG 35-55 -immunized CCR5 −/− mice and 3.1±1.2 in MOG 35-55 -immunized CCR5 +/+ mice. Mean day of onset was the same for CCR5 +/+ (11.8±1.8) and CCR5 −/− (11.2±1.8) mice. Mean body weight (g) was compared to day 0 in each group after injection of saline or MOG 35-55 for 28 days C. At day 28, control mouse body weight had increased 3.8±2.2 g, but had decreased 3.2±3.2 g and 2.6±3.0 g in MOG35-55-immunized CCR5 +/+ and CCR5 −/− mice, respectively. Weight loss (%) was not different between MOG 35-55 -induced CCR5 +/+ (14.6±13.8) and CCR5 −/− (11.4±13.4) mice D. Values are presented as mean ± SEM. # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.

Article Snippet: Cells were maintained in a humidified incubator at 37°C and 5% CO 2 , and were treated simultaneously with con A (4 μg/mL) and a CCR5 antagonist (D-Ala 1 -peptide T-NH 2 ; DAPTA; Bachem Bioscience Inc., King of Prussia, PA) (10 μM) dissolved in distilled water.

Techniques: Control, Saline, Injection

Cell infiltration A. and demyelination B. was greater in MOG 35-55 -immunized CCR5 +/+ mice than in MOG 35-55 -immunized CCR5 −/− mice.

Journal: Oncotarget

Article Title: CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice

doi: 10.18632/oncotarget.8097

Figure Lengend Snippet: Cell infiltration A. and demyelination B. was greater in MOG 35-55 -immunized CCR5 +/+ mice than in MOG 35-55 -immunized CCR5 −/− mice.

Article Snippet: Cells were maintained in a humidified incubator at 37°C and 5% CO 2 , and were treated simultaneously with con A (4 μg/mL) and a CCR5 antagonist (D-Ala 1 -peptide T-NH 2 ; DAPTA; Bachem Bioscience Inc., King of Prussia, PA) (10 μM) dissolved in distilled water.

Techniques:

TNF-α protein expression in MOG 35-55 -immunized CCR5 +/+ and CCR5 −/− mouse spinal cords B. IFN-γ expression was not significantly different between MOG 35-55 -immunized CCR5 +/+ and CCR5 −/− mouse spinal cords C. MOG 35-55 injection increased IL-1β expression in CCR5 +/+ mice compared to CCR5 −/− mice D. MCP-1 expression in MOG 35-55 -immunized CCR5 +/+ mice was higher than in CCE5 −/− mice. Values are presented as mean ± SEM. * p < 0.05 compared to control, # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.

Journal: Oncotarget

Article Title: CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice

doi: 10.18632/oncotarget.8097

Figure Lengend Snippet: TNF-α protein expression in MOG 35-55 -immunized CCR5 +/+ and CCR5 −/− mouse spinal cords B. IFN-γ expression was not significantly different between MOG 35-55 -immunized CCR5 +/+ and CCR5 −/− mouse spinal cords C. MOG 35-55 injection increased IL-1β expression in CCR5 +/+ mice compared to CCR5 −/− mice D. MCP-1 expression in MOG 35-55 -immunized CCR5 +/+ mice was higher than in CCE5 −/− mice. Values are presented as mean ± SEM. * p < 0.05 compared to control, # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.

Article Snippet: Cells were maintained in a humidified incubator at 37°C and 5% CO 2 , and were treated simultaneously with con A (4 μg/mL) and a CCR5 antagonist (D-Ala 1 -peptide T-NH 2 ; DAPTA; Bachem Bioscience Inc., King of Prussia, PA) (10 μM) dissolved in distilled water.

Techniques: Expressing, Injection, Control

CD3 + , CD4 + , CD8 + T cells did not infiltrate control mouse spinal cord tissue. MOG 35-55 -induced mouse spinal cord tissues showed infiltrating CD3 + , CD4 + , CD8 + T cells A. - C. Values are presented as mean ± SEM. ( n = 3) * p < 0.05 compared to control, # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.

Journal: Oncotarget

Article Title: CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice

doi: 10.18632/oncotarget.8097

Figure Lengend Snippet: CD3 + , CD4 + , CD8 + T cells did not infiltrate control mouse spinal cord tissue. MOG 35-55 -induced mouse spinal cord tissues showed infiltrating CD3 + , CD4 + , CD8 + T cells A. - C. Values are presented as mean ± SEM. ( n = 3) * p < 0.05 compared to control, # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.

Article Snippet: Cells were maintained in a humidified incubator at 37°C and 5% CO 2 , and were treated simultaneously with con A (4 μg/mL) and a CCR5 antagonist (D-Ala 1 -peptide T-NH 2 ; DAPTA; Bachem Bioscience Inc., King of Prussia, PA) (10 μM) dissolved in distilled water.

Techniques: Control

CNPase (myelinating oligodendrocyte marker) A. and NG2 (oligodendrocyte precursor maker) B. expression decreased in MOG 35-55 -induced CCR5 +/+ mouse spinal cords as compared to CCR5 −/− mice spinal cord. Values are presented as mean ± SEM. ( n = 3) * p < 0.05 compared to control, # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.

Journal: Oncotarget

Article Title: CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice

doi: 10.18632/oncotarget.8097

Figure Lengend Snippet: CNPase (myelinating oligodendrocyte marker) A. and NG2 (oligodendrocyte precursor maker) B. expression decreased in MOG 35-55 -induced CCR5 +/+ mouse spinal cords as compared to CCR5 −/− mice spinal cord. Values are presented as mean ± SEM. ( n = 3) * p < 0.05 compared to control, # p < 0.05 compared to MOG 35-55 -immunized CCR5 +/+ mice.

Article Snippet: Cells were maintained in a humidified incubator at 37°C and 5% CO 2 , and were treated simultaneously with con A (4 μg/mL) and a CCR5 antagonist (D-Ala 1 -peptide T-NH 2 ; DAPTA; Bachem Bioscience Inc., King of Prussia, PA) (10 μM) dissolved in distilled water.

Techniques: Marker, Expressing, Control